Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04735406 · ClinicalTrials.gov registry record

The MS-LINK™ Outcomes Study

A clinical trial of Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute.

Completed
Registry status
2,182
Enrollment target
9
Study locations

NCT04735406: Completed study of Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute.

NCT04735406 is a study of Multiple Sclerosis that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 2,182 participants, above the 578-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (278% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04735406, a study of Multiple Sclerosis, has completed, sponsored by EMD Serono Research & Development Institute.

COMPLETED
Registry status
2,182 participants
Enrollment target
9
Study locations

Study Summary

The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction from the participant's electronic medical record (EMR) and other health information systems (for example, radiology). Participants will complete patient-reported outcomes (PROs) and other health-related information digitally. Participating participants will have access to their own data in an ongoing manner via a web-based Participant Portal.

Conditions Studied

Study Locations (9)

Texas

  • The University of Texas of Austin - Austin
  • University of Texas Health - San Antonio

Alabama

  • Alabama Neurology Associates - Birmingham

District of Columbia

  • Georgetown University - Washington D.C.

Georgia

  • Atlanta Neuroscience Institute - Atlanta

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Michigan

  • Memorial healthcare - Owosso

Nebraska

  • University of Nebraska medical Center - Omaha

Oklahoma

  • The Oklahoma Medical Research Foundation - Oklahoma City

Trial Details

FieldValue
Enrollment Target 2,182 participants
Start Date 2021-03-24
Est. Completion 2024-05-31

What the finished NCT04735406 record still lists

NCT04735406 is an observational study that tracks outcomes without assigning an intervention. Its 2,182 participants enrollment target places it among the larger protocols in the corpus, above the 578-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (278% higher).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT04735406 lists 9 locations in 8 states (Texas, Alabama, District of Columbia).

Frequently Asked Questions

What is clinical trial NCT04735406 about?

NCT04735406 is a clinical study titled "The MS-LINK™ Outcomes Study". The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the stu...

What is the current status of trial NCT04735406?

This trial is currently completed. The enrollment target is 2,182 participants. The study started on 2021-03-24. Estimated completion is 2024-05-31.

What conditions does trial NCT04735406 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT04735406?

This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04735406 being conducted?

This trial has 9 study locations across Alabama, District of Columbia, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04735406's enrollment target sits among peer trials

2,182 14th of 315 higher than 302 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05917652 · 2,183 participants

    The Actuate-CBC Study

  • NCT05654207 · 2,200 participants · NA

    WeCare: A System of Care for Black Youth

  • NCT06144554 · 2,200 participants

    Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

  • NCT06526988 · 2,200 participants · NA

    Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04735406, the US trial registry maintained by the National Library of Medicine. NCT04735406 (large enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.